Federal Register / Vol. 61, No. 84 / Tuesday, April 30, 1996 / Notices 19073

Respondents No. of

responses

No. of responses/respondentAverage burden/response

(in hrs.)

Total burden (in hrs.)

Induction ......................................................................................................................... 40 1 1.5 60

Out-of-scope Verification ................................................................................................ 140 1 0.066 9

Sample Listing Sheet:

ASC Personnel ........................................................................................................ 224 12 0.5 1,344

Census Personnel ................................................................................................... 267 12 0 0

Medical Abstract:

ASC Personnel ........................................................................................................ 324 250 0.2 16,200

Census Personnel ................................................................................................... 167 250 0.03333 1,392

Annual Update ................................................................................................................ 491 1 0.083 41

Quality Control ................................................................................................................ 245 200 .0333 163

Total ................................................................................................................. .................... .................... ...................... 19,209

Dated: April 24, 1996.

Wilma G. Johnson,

Acting Associate Director for Policy Planning

and Evaluation, Centers for Disease Control

and Prevention (CDC).

[FR Doc. 96–10627 Filed 4–29–96; 8:45 am]

BILLING CODE 4163–18–P

National Center for Health Statistics;

ICD–9–CM E Code Revisions

AGENCY: National Center for Health

Statistics, Centers for Disease Control

and Prevention (CDC), DHHS.

ACTION: Notice.

SUMMARY: The National Center for

Health Statistics has approved the

following expansion to the External

Cause Codes in the International

Classification of Diseases, Ninth

Revision, Clinical Modification (ICD–9–

CM). These ICD–9–CM E-Code revisions

will become effective October 1, 1996.

The official guidelines for the

application of E-codes for morbidity

purposes will also be updated at that

time. The official government version of

the ICD–9–CM which will include all

the revisions effective October 1, 1996,

will be found on the ICD–9–CM CD–

ROM which will be available through

the Government Printing Office.

E967 Child and adult battering and

other maltreatment

E967.0 By father or stepfather

E967.2 By mother or stepmother

E967.3 By spouse or partner

E967.4 By child

E967.5 By sibling

E967.6 By grandparent

E967.7 By other relative

E967.8 By non-related caregiver

FOR FURTHER INFORMATION CONTACT:

Donna Pickett, R.R.A., Co-chair, ICD–9–

CM Coordination and Maintenance

Committee, National Center for Health

Statistics, CDC, telephone (301) 436–

7050.

Dated: April 24, 1996.

Joseph R. Carter,

Acting Associate Director for Management

and Operations, Centers for Disease Control

and Prevention (CDC).

[FR Doc. 96–10628 Filed 4–29–96; 8:45 am]

BILLING CODE 4163–18–P

[Announcement 619]

HIV-Related Tuberculosis Preventive

Therapy Regimen Demonstration

Cooperative Agreements

Introduction

The Centers for Disease Control and

Prevention (CDC) announces the

availability of fiscal year (FY) 1996

funds to continue the cooperative

agreement program started in FY 1992

through announcement number 261

entitled ‘‘Human Immunodeficiency

Virus (HIV) Related Tuberculosis (TB)

Preventive Therapy Regimen (PTR)

Demonstration Cooperative

Agreements.’’ Current recipients will

compete to extend the project period for

an additional three years to allow

sufficient time to actively monitor and

ensure compliance with drug therapy,

assess toxicity, and appropriately

evaluate patients for up to two years

after completion of preventive therapy.

All applicants, however, who meet the

eligibility criteria will be considered.

See the section entitled Eligible

Applicants.

CDC is committed to achieving the

health promotion and disease

prevention objectives of ‘‘Healthy

People 2000,’’ a national activity to

reduce morbidity and mortality and

improve the quality of life. This

announcement is related to the priority

areas of HIV Infection and

Immunization and Infectious Diseases.

(For ordering a copy of ‘‘Healthy People

2000,’’ see the section Where To Obtain

Additional Information.)

Authority

This program is authorized under

Section 317E of the Public Health

Service Act, [42 U.S.C. 247b–6], as

amended.

Smoke-Free Workplace

CDC strongly encourages all grant

recipients to provide a smoke- free

workplace and to promote the non-use

of all tobacco products, and Public Law

103–227, the Pro-Children Act of 1994,

prohibits smoking in certain facilities

that receive Federal funds in which

education, library, day care, health care,

and early childhood development

services are provided to children.

Eligible Applicants

Applications may be submitted by

public and private, nonprofit and forprofit organizations and governments

and their agencies. Thus, universities,

and colleges; and research institutions,

hospitals, other public and private

organizations, State and local

governments or their bonafide agents,

federally recognized Indian tribal

governments, Indian tribes or Indian

tribal organizations, and small,

minority- and/or women-owned

businesses are eligible to apply.

Applicants must have the ability to (1)

identify, obtain informed consent, and

enroll a minimum of 25 dually-infected

(TB/HIV-infected) persons and start

them on one of two TB preventive

regimens according to the

randomization schedule provided by

CDC and (2) conduct patient follow-up

according to accepted clinical study

practices. A copy of the prescribed

regimens is included in the application

kit. Applicants must be able to complete

all phases of the project within the

proposed three year project period.

Preference will be given to competing

continuation applications submitted by

the current cooperative agreement

recipients funded in FY 1992 through

competitive announcement number 261

entitled ‘‘Human Immunodeficiency